Oktober 2023
NOK 505 million
Transaction Highlights
- Capital increase raising NOK 505m (c. EUR 43m) via a placement of 29.6m new shares, representing a 10% increase
- The order book was multiple times oversubscribed and saw significant demand from new international investors, demonstrated by the largest existing shareholders not being allocated any shares in the offering, while initially having pre-committed up to NOK 330m
- Nykode, the largest Norwegian biotech company by market cap, intends to use the proceeds to advance its lead cancer immunotherapy VB10.16, pipeline and proprietary Vaccibody technology platform
- This transaction represents Van Lanschot Kempen’s fourth ECM transaction for a Nordic Life Sciences company in 2023, underpinning the ability of Van Lanschot Kempen to support companies in the Nordic.
Company Description
Nykode is a Norwegian clinical-stage biopharmaceutical company developing cancer immunotherapies based on its proprietary Vaccibody vaccination technology. Nykode's lead asset, VB10.16, is a therapeutic vaccine against HPV16+ cancers and is currently in Phase II development for cervical cancer and HNSCC. The Company has high profile R&D collaborations with Roche/Genentech, Regeneron and Adaptive Biotechnologies
Van Lanschot Kempen Life Sciences & Healthcare credentials
In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:
- Sole Financial Adviser in the SEK 120 million Structured Equity transaction by Synact Pharma
- Lead Manager in the USD 173 million Capital Increase by Merus
- Manager in the USD 1.3 billion Capital Increase by argenx
- Joint Bookrunner in the SEK 500 million Capital Increase by Vicore Pharma
- Financial Adviser to NewAmsterdam Pharma in the USD 182 million secondary sell-down by existing investors
- Joint Global Coordinator & Joint Bookrunner in the EUR 25 million Capital Increase by Vivoryon Therapeutics
- Joint Global Coordinator & Joint Bookrunner in the EUR 16 million Capital Increase by Sequana Medical
- Lead Manager in the DKK 1.5 billion Capital Increase by Zealand Pharma
- Capital Markets Advisor & Placement Agent in the merger between European Biotech Acquisition Corp. and Oculis SA and the connected USD 91 million PIPE
- Lead Manager in the USD 250 million Capital Increase by CureVac
- Sole Financial Adviser to GenSight Biologics in securing a EUR 12 million credit facility from Heights Capital Management
- Joint Global Coordinator and Joint Bookrunner in the SEK 416 million Capital Increase by Hansa Biopharma
- Sole Financial Adviser in SynAct Pharma’s acquisition of TXP Pharma and Joint Global Coordinator & Joint Bookrunner in SynAct Pharma’s SEK 80 million PIPE
- Joint Bookrunner in the SEK 200 million Capital Increase by Vicore Pharma
- Joint Global Bookrunner in the SEK 148 million Fully Guaranteed Rights Issue by Biovica
- Financial Adviser to GenSight Biologics in securing a EUR 35 million credit facility from the European Investment Bank
- Joint Global Coordinator & Joint Bookrunner in the SEK 170 million Capital Increase by Xbrane Biopharma
- Co-Lead Manager in the DKK 786 million Capital Increase by Zealand Pharma